NeoGenomics director gets stock, option awards
NeoGenomics Inc. director David Brian Perez reported multiple equity compensation movements.
Rhea-AI Filing Summary
NeoGenomics Inc. director David Brian Perez reported multiple equity compensation movements. On June 1, 2026, he exercised restricted stock units into 23,077 shares of common stock, bringing his direct common stock holdings to 56,967 shares. He also received a new grant of 15,970 restricted stock units, each convertible into one share of common stock, and a new stock option for 11,069 shares with a strike price of $10.52 per share expiring in 2036. Perez continues to hold 10,000 common shares indirectly through the Perez Joint Revocable Trust. The filing shows no open‑market buys or sells, only option and RSU grants and exercises related to compensation.
Positive
- None.
Negative
- None.
Insider Trade Summary
23,077 shares exercised/converted
Exercise
9 txns
Insider
Perez David Brian
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 23,077 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) | 11,069 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Unit | 15,970 | $0.00 | $0.00 |
| Exercise | Common Stock | 23,077 | $0.00 | $0.00 |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Unit — 15,970 contracts (Direct);
Stock Option (Right to Buy) — 53,931 contracts for 42,862 underlying shares (Direct);
Common Stock — 56,967 shares (Direct);
Common Stock — 10,000 shares (Indirect, Perez Joint Revocable Trust David & Karen Perez TTEE U/A Dated 12/09/2016)
Footnotes (2)
- F1. Reflects release of restricted stock units that were previously reported on a Form 4.
- F2. Once vested, the shares of common stock are not subject to expiration.
Key Figures
RSUs exercised into common stock: 23,077 shares
Direct common stock holdings: 56,967 shares
Indirect common stock holdings: 10,000 shares
+5 more
8 metrics
RSUs exercised into common stock
23,077 shares
Restricted stock units converted to common stock on June 1, 2026
Direct common stock holdings
56,967 shares
Common stock directly owned after transactions
Indirect common stock holdings
10,000 shares
Held via Perez Joint Revocable Trust after transactions
New RSU grant
15,970 units
Restricted stock units granted on June 1, 2026
New stock option grant
11,069 options at $10.52
Option to buy common stock, expiring June 1, 2036
Existing option at $7.28
16,107 underlying shares
Stock option expiring June 1, 2035, direct ownership
Existing option at $13.71
8,672 underlying shares
Stock option expiring June 1, 2034, direct ownership
Existing option at $7.34
9,730 underlying shares
Stock option expiring June 10, 2029, direct ownership
Key Terms
Restricted Stock Unit, Stock Option (Right to Buy), derivative exercise/conversion, grant/award acquisition, +1 more
5 terms
Restricted Stock Unit financial
"security_title: "Restricted Stock Unit" with 15,970.0000 shares granted"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with exercise prices and expirations"
derivative exercise/conversion financial
"transaction_action: "derivative exercise/conversion" for RSUs into common stock"
grant/award acquisition financial
"transaction_action: "grant/award acquisition" for new RSU and option grants"
indirect financial
"ownership_type: "indirect" for shares held via Perez Joint Revocable Trust"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NeoGenomics (NEO) director David Brian Perez report in this Form 4?
David Brian Perez reported equity compensation activity, including exercising restricted stock units into 23,077 common shares and receiving new grants of restricted stock units and stock options. The filing shows no open-market purchases or sales, only compensation-related awards and exercises.
What restricted stock unit activity did NeoGenomics (NEO) disclose for David Brian Perez?
Perez exercised restricted stock units into 23,077 NeoGenomics common shares and received a new grant of 15,970 restricted stock units. Each unit represents a right to receive one common share, subject to vesting and the terms described in the award.
What new stock option grant did David Brian Perez receive from NeoGenomics (NEO)?
Perez received a stock option covering 11,069 NeoGenomics common shares at an exercise price of $10.52 per share, expiring in 2036. This option was reported as a grant or award acquisition, reflecting equity-based compensation rather than an open-market purchase.
Were there any open-market stock sales or purchases in this NeoGenomics (NEO) Form 4?
The Form 4 shows no open-market purchases or sales by David Brian Perez. Reported transactions are derivative exercises and grants, including RSUs converted into common stock and new RSU and option awards, all at a reported price of $0.00 per unit or option.
What other stock options does David Brian Perez hold at NeoGenomics (NEO)?
Perez holds several option awards on NeoGenomics common stock, including tranches with exercise prices of $7.28, $7.34, $13.71, and $14.82, with expiration dates ranging from 2029 to 2035. These options cover underlying share amounts disclosed in the filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
